Clinical Trials · NCT06056804
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Beijing Friendship Hospital
- Enrollment
- 20
- Start date
- Jan 2024
- Locations
- 2 sites, China
- Primary endpoint
- CR rate